Cancer Home > Gliadel Efficacy

Gliadel® (carmustine implant) is a prescription chemotherapy medicine used to treat certain types of brain tumors called malignant glioma and glioblastoma multiforme. It belongs to a group of medicines known as nitrosoureas.
In clinical studies examining the efficacy of Gliadel, the drug was shown to improve survival in people with newly diagnosed cancerous brain tumors. One study showed that people who received Gliadel had a median survival of 13.8 months, compared with a median survival of 11.6 months in people who were given a placebo implant (an implant that did not contain any active ingredients).
(Click Gliadel to learn more about this drug's safety and efficacy, as well as dosing guidelines, potential side effects, and more.)
Written by/reviewed by:
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
List of references (click here):



Related Channels

eMedTV Links
Copyright © 2006-2019 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.